Drug intelligence / Profile preview

KBA-1636

Development stage: Preclinical
Lead developer: Kling Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

KBA-1636 is a monoclonal antibody drug candidate developed by Kling Biotherapeutics. It acts as an inhibitor of cadherin 1 (CDH1), targeting this protein to disrupt its function. The primary therapeutic areas under investigation for KBA-1636 include neoplasms (notably colonic cancer) and congenital or digestive system disorders, with specific active indications in colonic cancer and Lynch syndrome II. As of the latest update, the drug remains in preclinical development[1].

Targets

sEcad (Soluble E-cadherin)

Beyond the preview

Go deeper on KBA-1636.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBA-1636.

Explore the full profile